Rydén, Lars

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology

Hyperglycemia and glycemic control in critically ill and hospitalized patientsAcute Myocardial Infarction Research

Cited by 1,560

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L., Marx, N., Brosius, F. C., Mustafa, R. A., Agarwal, A., et al. (2023) · BMJ

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 293

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 238

Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology

On behalf of the EUROASPIRE Investigators, Gyberg, V., De Bacquer, D., De Backer, G., Jennings, C., Kotseva, K., Mellbin, L., Schnell, O., Tuomilehto, J., Wood, D., et al. (2015) · Cardiovascular Diabetology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 140

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 137

The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV

Shahim, B., De Bacquer, D., De Backer, G., Gyberg, V., Kotseva, K., Mellbin, L., Schnell, O., Tuomilehto, J., Wood, D., & Rydén, L. (2017) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 114

Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort

Ritsinger, V., Tanoglidi, E., Malmberg, K., Näsman, P., Rydén, L., Tenerz, Å., & Norhammar, A. (2015) · Diabetes and Vascular Disease Research

Diabetes, Cardiovascular Risks, and LipoproteinsAcute Myocardial Infarction Research

Cited by 71

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial

Mellbin, L. G., Malmberg, K., Rydén, L., Wedel, H., Vestberg, D., & Lind, M. (2013) · European Heart Journal

Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Management and Research

Cited by 57

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys

EUROASPIRE IV & V Investigators, Ferrannini, G., De Bacquer, D., Vynckier, P., De Backer, G., Gyberg, V., Kotseva, K., Mellbin, L., Norhammar, A., Tuomilehto, J., et al. (2021) · Cardiovascular Diabetology

Sex and Gender in HealthcareDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 54

Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes

Johansson, I., Dahlström, U., Edner, M., Näsman, P., Rydén, L., & Norhammar, A. (2015) · Heart

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 41

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Dagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35

Patients with type 2 diabetes have an increased demand for pacemaker treatment: a comparison with age-and sex-matched control subjects from the general population

Rautio, E., Gadler, F., Gudbjörnsdottir, S., Franzén, S., Rydén, L., Svensson, A.-M., & Mellbin, L. G. (2020) · Diabetes Care

Cardiac pacing and defibrillation studiesCardiac electrophysiology and arrhythmias

Cited by 23